17 May 2013 - 17 May 2013 - Australian QRxPharma Limited (ASX:QRX) said today that the US FDA's Advisory Committee will meet on 17 July to consider its resubmitted New Drug Application (NDA) for MOXDUO for the treatment of acute pain.

The Committee will review respiratory safety data comparing the therapy with its components.

The company's managing director and CEO Dr John Holaday said that the formal notification of the Advisory Committee date finalises the sequence of events which led to the previously announced PDUFA action date of 26 August.

MOXDUO, which is an immediate release Dual Opioid pain therapy, is a 3:2 fixed ratio combination of morphine and oxycodone.